Aurobindo Pharma

Aurobindo Pharma | September 29, 2016

The generic drugmaker Aurobindo Pharma U.S.A. Inc. will not longer be pursuing $200,000 in incentives through the city of Durham. The city was alerted to the agreement termination in a letter from the company on September 6. The city council was told today in an email from city manager Tom Bonfield…...

Brand India Pharma | January 03, 2017

Aurobindo Pharma Limited has received US Food &Drug Administration (USFDA) approval to make and market heartburn relief medicine Famotidine tablets of strengths 10 mg and 20 mg and Oxymorphone Hydrochloride Tablets of strengths 5 mg and 10 mg . The estimated market size for Famotidine for the 12 month period ending February 2016 was US$ 31 million whereas for Oxymorphone Hydrochloride Tablets, it is US$ 55.5 million for the same period as per data by IMS....

Aurobindo Pharma USA, Inc. | February 13, 2017

Indian company Aurobindo Pharma has acquired four cell culture-derived biosimilar products from Swiss-based TL Biopharmaceutical. Under the agreement, TL will supply all the developmental data for four molecules and the products will be globally developed, commercialised and marketed by Aurobindo and its affiliates....

Business Today | March 15, 2017

Drug firm Aurobindo Pharma has received final approval from USFDA to manufacture and market Ibandronate Sodium tablets....